CSTL Share Price Performance
US$25.56
6.27 (32.50%)
47.3% undervalued intrinsic discount
US$48.50
Fair Value
Price US$25.56
AnalystConsensusTarget US$48.50
AnalystLowTarget US$30.00
AnalystHighTarget US$52.00
Fair ValueUS$48.50
Share Pricen/a
Castle Biosciences, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
CSTL Community Narratives
AN
Fair Value US$48.5 47.3% undervalued intrinsic discount
Expanding Diagnostic Menus Will Unlock Broad Clinical Potential
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$30 14.8% undervalued intrinsic discount
Payer Scrutiny And Coverage Risks Will Limit Long-Term Precision Dermatology Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$52 50.8% undervalued intrinsic discount
Atopic Dermatitis Opportunity And Expanding Test Adoption Will Transform Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Expanding Diagnostic Menus Will Unlock Broad Clinical Potential
Key Takeaways Expanding into new diagnostic areas and strengthening real-world clinical evidence is poised to enhance adoption, diversify revenue, and drive long-term growth. Advances in reimbursement, physician education, and sales force maturity are expected to improve pricing, margins, and market penetration.Read more
91
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$48.5
47.3% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
5.56%
Future PE
78.77x
Price in 2029
US$58.53
Atopic Dermatitis Opportunity And Expanding Test Adoption Will Transform Long Term Outlook
Catalysts About Castle Biosciences Castle Biosciences develops and commercializes gene expression profile tests that help physicians personalize treatment decisions in dermatology and gastroenterology. What are the underlying business or industry changes driving this perspective?Read more
1
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$52
50.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Profit Margin
5.41%
Future PE
86.66x
Price in 2029
US$63.62
Payer Scrutiny And Coverage Risks Will Limit Long-Term Precision Dermatology Potential
Catalysts About Castle Biosciences Castle Biosciences develops and commercializes diagnostic tests that use molecular and gene expression profiling to guide treatment decisions in dermatology and gastroenterology. What are the underlying business or industry changes driving this perspective?Read more
8
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$30
14.8% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Profit Margin
5.45%
Future PE
55.58x
Price in 2028
US$36.71
Trending Discussion
Recently Updated Narratives
AN
CSTL: Preliminary 2025 Revenue Outlook Will Support Higher 2026 Expectations
Fair Value: US$48.5 47.3% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Atopic Dermatitis Opportunity And Expanding Test Adoption Will Transform Long Term Outlook
Fair Value: US$52 50.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Payer Scrutiny And Coverage Risks Will Limit Long-Term Precision Dermatology Potential
Fair Value: US$30 14.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Castle Biosciences, Inc. Key Details
About CSTL
- Founded
- 2007
- Employees
- 883
- CEO
- WebsiteView website
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
